Why the study?
Patients with coronary artery disease and impaired renal function face increased risk for both bleeding and ischemic events after PCI, prompting assessment of a prasugrel-based de-escalation strategy across renal function levels.
Does a prasugrel-based de-escalation strategy improve bleeding and ischemic outcomes in patients with acute coronary syndrome receiving PCI across different levels of renal function?
Does a prasugrel-based de-escalation strategy improve bleeding and ischemic outcomes in patients with acute coronary syndrome receiving PCI across different levels of renal function?
Prasugrel dose de-escalation appears beneficial and safe in ACS patients undergoing PCI regardless of their baseline renal function.
Answers are grounded in this paper and cite their sources.
Supports prasugrel de-escalation across renal strata in ACS-PCI; hypothesis-generating, requires randomized confirmation.
Background: Patients with coronary artery disease and impaired renal function are at higher risk for both bleeding and ischemic adverse events after percutaneous coronary intervention (PCI). Objectives: This study assessed the efficacy and safety of a prasugrel-based de-escalation strategy in patients with impaired renal function. Methods: We conducted a post hoc analysis of the HOST-REDUCE-POLYTECH-ACS study. Patients with available estimated glomerular filtration rate (eGFR) (n = 2,311) were categorized into 3 groups. (high eGFR: >90 mL/min; intermediate eGFR: 60 to 90 mL/min; and low eGFR: <60 mL/min). The end points were bleeding outcomes (Bleeding Academic Research Consortium type 2 or higher), ischemic outcomes (cardiovascular death, myocardial infarction, stent thrombosis, repeated revascularization, and ischemic stroke), and net adverse clinical event (including any clinical event) at 1-year follow-up. Results: for interaction = 0.119). Conclusions: In patients with acute coronary syndrome receiving PCI, prasugrel dose de-escalation was beneficial regardless of the baseline renal function.
No takes yet. Share an insight, caveat, or question.
Yun et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: